Nasdaq · CIK 0001706431
VIR Vir Biotechnology, Inc.
Insider trading from SEC Form 4. Last filing Jul 17, 2025. Close $11.70 on Oct 9, 2026, +129% from the 52-week low and -1% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
VIROct 9, 2026 · close 11.70
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Vir Biotechnology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 2Weak | Mark Eisner EVP and Chief Medical Officer sell | $57k 10,382 shares | -9% | +18% from low-58% from high | |
| 0Weak | Janet Napolitano director sell | $16k 3,200 shares | -16% | +13% from low-59% from high | |
| 22Weak | Marianne De Backer Chief Executive Officer sell | $474k 79,712 shares | -9% | 0% from low-52% from high | |
| 24Weak | Marianne De Backer Chief Executive Officer sell | $152k 16,122 shares | -2% | - | |
| 19Weak | Ann M. Hanly EVP & Chief Technology Officer sell | $134k 14,168 shares | -11% | - | |
| 15Weak | Vanina de Verneuil EVP and General Counsel sell | $625 76 shares | -0% | - | |
| 1Weak | Vanina de Verneuil EVP and General Counsel sell | $44k 4,397 shares | -7% | - | |
| 0Weak | Vanina de Verneuil EVP and General Counsel sell | $32k 3,750 shares | -6% | - |
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 15, 2025 | Mark Eisner EVP and Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -6,796 | $5.47 | $37k | 108,204 | Jul 17, 2025 |
| Jul 17, 2025 | Mark Eisner EVP and Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,586 | $5.47 | $20k | 104,618 | Jul 17, 2025 |
| Jun 9, 2025 | Robert J More director | JOther Common Stock | -14,027 | $0.00 | $0 | 40,656 | Jun 9, 2025 |
| Jun 9, 2025 | Robert J More director | JOther Common Stockindirect: See footnote | +14,027 | $0.00 | $0 | 509,917 | Jun 9, 2025 |
| Jun 6, 2025 | Norbert W Bischofberger director | JOther Common Stock | -10,667 | $0.00 | $0 | 13,333 | Jun 6, 2025 |
| Jun 6, 2025 | Norbert W Bischofberger director | JOther Common Stockindirect: See footnote | +10,667 | $0.00 | $0 | 10,667 | Jun 6, 2025 |
| May 30, 2025 | Charles Elliott Sigal director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 31,806 | Jun 2, 2025 |
| May 30, 2025 | Norbert W Bischofberger director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 24,000 | Jun 2, 2025 |
| May 30, 2025 | Ramy Farid director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 24,000 | Jun 2, 2025 |
| May 30, 2025 | Vicki L Sato director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 1,320,391 | Jun 2, 2025 |
| May 30, 2025 | Jeffrey S. Hatfield director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 31,806 | Jun 2, 2025 |
| May 30, 2025 | Robert J More director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 54,683 | Jun 2, 2025 |
| May 30, 2025 | Saira Ramasastry director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 22,619 | Jun 2, 2025 |
| May 30, 2025 | Janet Napolitano director | AGrant or award Common Stock10b5-1 | +8,000 | $0.00 | $0 | 19,616 | Jun 2, 2025 |
| May 30, 2025 | Vicki L Sato director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Saira Ramasastry director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Jeffrey S. Hatfield director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Ramy Farid director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Norbert W Bischofberger director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| Jun 2, 2025 | Janet Napolitano director | SOpen-market sale Common Stock10b5-1 | -3,200 | $5.05 | $16k | 16,416 | Jun 2, 2025 |
| May 30, 2025 | Robert J More director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Charles Elliott Sigal director | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| May 30, 2025 | Janet Napolitano director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| Apr 3, 2025 | Marianne De Backer Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -79,712 | $5.95 | $474k | 769,505 | Apr 4, 2025 |
| Feb 22, 2025 | Mark Eisner EVP and Chief Medical Officer | AGrant or award Common Stock10b5-1 | +40,000 | $0.00 | $0 | 115,000 | Feb 25, 2025 |
| Feb 22, 2025 | Marianne De Backer Chief Executive Officer | AGrant or award Common Stock10b5-1 | +240,000 | $0.00 | $0 | 865,339 | Feb 25, 2025 |
| Feb 24, 2025 | Ann M. Hanly EVP & Chief Technology Officer | SOpen-market sale Common Stock10b5-1 | -14,168 | $9.45 | $134k | 117,901 | Feb 25, 2025 |
| Feb 24, 2025 | Marianne De Backer Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -16,122 | $9.45 | $152k | 849,217 | Feb 25, 2025 |
| Feb 22, 2025 | Mark Eisner EVP and Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +80,000 | $0.00 | $0 | 80,000 | Feb 25, 2025 |
| Feb 22, 2025 | Marianne De Backer Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +480,000 | $0.00 | $0 | 480,000 | Feb 25, 2025 |
| Dec 2, 2024 | Vanina de Verneuil EVP and General Counsel | SOpen-market sale Common Stock | -76 | $8.22 | $625 | 56,973 | Dec 4, 2024 |
| Nov 15, 2024 | Jason O'Byrne EVP & Chief Financial Officer | AGrant or award Common Stock10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Nov 18, 2024 |
| Nov 15, 2024 | Jason O'Byrne EVP & Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +150,000 | $0.00 | $0 | 150,000 | Nov 18, 2024 |
| Nov 6, 2024 | Vanina de Verneuil EVP and General Counsel | SOpen-market sale Common Stock10b5-1 | -4,397 | $10.11 | $44k | 56,973 | Nov 7, 2024 |
| Nov 1, 2024 | Vanina de Verneuil EVP and General Counsel | SOpen-market sale Common Stock10b5-1 | -1,403 | $7.20 | $10k | 63,717 | Nov 5, 2024 |
| Nov 5, 2024 | Vanina de Verneuil EVP and General Counsel | SOpen-market sale Common Stock10b5-1 | -2,347 | $9.47 | $22k | 61,370 | Nov 5, 2024 |
| Oct 23, 2024 | George A Scangos director | JOther Common Stock | +598,270 | $0.00 | $0 | 719,259 | Oct 24, 2024 |
| Oct 23, 2024 | George A Scangos director | JOther Common Stockindirect: See footnote | -598,270 | $0.00 | $0 | 1,151,730 | Oct 24, 2024 |
| Oct 23, 2024 | George A Scangos director | JOther Common Stockindirect: See footnote | +598,270 | $0.00 | $0 | 598,270 | Oct 24, 2024 |
| Oct 23, 2024 | George A Scangos director | JOther Common Stockindirect: See footnote | -598,270 | $0.00 | $0 | 1,151,730 | Oct 24, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Norbert W Bischofbergerdirector, owner
- Marianne De BackerChief Executive Officer
- Mark EisnerEVP and Chief Medical Officer
- Ramy Faridceo, president, officer, director
- Ann M. HanlyEVP & Chief Technology Officer
- Jeffrey S. Hatfielddirector
- Robert J Moredirector
- Janet Napolitanodirector
- Jason O'ByrneEVP & Chief Financial Officer
- Saira Ramasastrydirector
- Vicki L Satodirector
- George A Scangosdirector
- Charles Elliott Sigaldirector
- Vanina de VerneuilEVP and General Counsel
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.